Mon, 16 Nov 2026
In the News

India proposes immediate suspension of substandard drug licences

Published · 1 min read

The Union Health Ministry seeks to amend the 1945 Drugs Rules so that licences can be halted instantly when a drug fails key quality tests.

India proposes immediate suspension of substandard drug licences
Photo: The Hindu

The Union Health Ministry announced on Wednesday, November 4, 2026, that it will amend the Drugs Rules, 1945 to allow the immediate suspension of manufacturing licences for medicines declared Not of Standard Quality (NSQ) on critical parameters such as assay, dissolution, related substances, impurities or sterility (The Hindu).

What changes are being introduced to the Drugs Rules?

The proposed amendment adds a provision for the Central Licensing Approving Authority or the State Licensing Authority to suspend a licence as soon as a government analyst’s report flags a drug as NSQ (The Hindu). This bypasses the current requirement of a show‑cause notice, which can create a gap between the NSQ declaration and regulatory action.

How will the suspension and reinstatement process work?

Suspension will stay in force until the manufacturer conducts a root‑cause analysis and implements corrective and preventive actions that satisfy the licensing authority, after which the licence may be reinstated (The Hindu). The amendment also mandates that the analyst’s report be shared with the Drugs Controller General of India, the relevant State/UT licensing authority, and the drug’s manufacturer and marketer to ensure coordinated action.

When can the public comment on the draft amendments?

The draft rules have been released for public consultation, with stakeholders invited to submit objections or suggestions in English within 30 days of the Gazette of India publishing the draft (The Hindu).

This report is based on original reporting by The Hindu. Read the original source →

#India#health ministry#drug regulation#pharmaceutical quality#public health